[Skip to Content]
[Skip to Content Landing]
February 15, 2006


Author Affiliations

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2006;295(7):756-758. doi:10.1001/jama.295.7.757-a

To the Editor: The study by Dr Lanfear and colleagues1 showed an apparent disconnect between the effects that ADRB2 and ADRB1 variants have on survival in patients receiving β-blockers after an acute coronary syndrome. The homozygous composite genotypes comprising Arg-Arg16 /Gln-Gln 27 (46AA/79CC) and Gly-Gly16/Glu-Glu 27 (46GG/79GG) were associated with a higher and lower risk of death, respectively, amounting to a 14% difference in mortality rate over 3 years.